Bristol-Myers Squibb Co. (BMY) and the Gladstone Institutes announced the formation of a discovery-based research collaboration to identify and validate novel targets in Alzheimer's disease.
As per the agreement, Bristol-Myers Squibb will fund Gladstone's research efforts to identify targets that affect Tau dysfunction. Tau is a protein that binds the cell's internal skeleton and may help regulate the activity of brain cells.
In Alzheimer's disease, Tau forms abnormal deposits called neurofibrillary tangles, a hallmark pathology of the disease. By identifying targets that prevent or reverse Tau dysfunction, Bristol-Myers Squibb and Gladstone hope to identify novel therapeutic strategies to modify the course of the disease.
For comments and feedback: editorial@rttnews.com